DGAP-News

Carl Zeiss Meditec posts slight revenue growth

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Final Results
Carl Zeiss Meditec posts slight revenue growth

08.12.2014 / 07:00

---------------------------------------------------------------------

Carl Zeiss Meditec posts slight revenue growth

Currency effects and regional variations in business burden results

JENA, 8 December 2014
Medical technology company Carl Zeiss Meditec AG closed financial year
2013/2014 with a slight growth in revenue from EUR 906 million to EUR 909
million, in spite of unfavorable currency trends. Adjusted for currency
effects, growth amounted to 3.0 percent. Earnings before taxes totaled EUR
120.7 million, which corresponds to an EBIT margin of 13.3 percent. The
company achieved substantial increases in case-number-dependent revenue
which accounted for as much as 28 percent of revenue in the financial year
just ended.

The Carl Zeiss Meditec Group achieved a balanced distribution of revenue
across its three regions of the world in financial year 2013/2014. The
development of its business units continued to be varied, however. A
negative valuation result from currency hedging transactions reduced
earnings per share, which reached EUR 0.92. The distribution of a regular
dividend of 40 cents shall be proposed to the Annual General Meeting; the
dividend ratio would therefore be slightly higher than the previous year,
at around 43%.

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, gave his take
on the figures: "In spite of adverse currency trends and to some extent
difficult markets, we have achieved a satisfactory result. The rise in
case-number-dependent revenue is a very positive development. Once again,
we achieved a significant increase in this area, to 28 percent."

Revenue by business unit

The Surgical Ophthalmology SBU achieved the strongest growth in financial
year 2013/2014, increasing its revenue by 20.3 percent compared with the
previous year to around EUR 146 million. Even without taking the
acquisition of Aaren Scientific into account, this SBU's growth would have
been in the double digits. The first intraocular lens (IOL) in the standard
segment to be jointly developed and produced in Ontario (USA), CT LUCIA,
was launched on the market at the end of the financial year. The successful
integration of this company, which was acquired at the beginning of 2014,
enables Carl Zeiss Meditec AG to offer its customers a particularly
comprehensive range of IOLs in the growth market for cataract surgery.

The Microsurgery SBU, which has traditionally been the strongest